Revolution Medicines' daraxonrasib doubles survival in Phase 3 pancreatic cancer trial

Revolution Medicines reported Phase 3 data: daraxonrasib plus chemotherapy extended survival to 13.2 months versus 6.7 months for chemo alone—a 6.5-month gain.